AI and Precision Medicine in Neuro-Oncology

AI and Precision Medicine in Neuro-Oncology

AI and Precision Medicine in Neuro-Oncology

Reach out to our imaging experts at

Link to access content

About the Webinar:

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

Join our live discussion with experts on how to incorporate an efficient imaging strategy and AI into drug development programs.

Key discussion points:

  • Modern trial infrastructure
  • Power of Artificial Intelligence (AI)
  • RANO, mRANO, iRANO: Choosing the right criteria
  • Impacting patient outcomes

Presenter: Dr. Sotirios Bisdas:
Head of Neuro-Oncology and Neurology clinical research at IAG, neuroradiologist, Associate Professor at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. Dr. Bisdas is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases.

Presenter: Dr. Andrew Patterson:
Dr Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.

Moderator: Julia O’Lynn:
With extensive expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials. Specializing in neuro-oncology, she helps build biotech partnerships exploring how advanced analysis, AI, and precision medicine can determine early efficacy.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:

Reach out:

Follow the Company: Linkedin